Treatment outcomes of multidrug-resistant tuberculosis patients in Gauteng, South Africa

Infection

Volumn 42, Issue 2, 2014, Pages 405-413

  Marais, E ^a   Mlambo, C K ^a   Lewis, J J ^b   Rastogi, N ^c   Zozio, T ^c   Grobusch, M P ^a,d   Duse, A ^a   Victor, T ^e   Warren, R W ^e  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Institut Pasteur de Guadeloupe   (Guadeloupe)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Multidrug resistant tuberculosis; South Africa; Treatment outcome

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENOTYPE; HEALTH CARE FACILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOLECULAR TYPING; MULTIDRUG RESISTANT TUBERCULOSIS; RETROSPECTIVE STUDY; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT OUTCOME; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; RISK FACTOR; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; FEMALE; GENOTYPE; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84897541977     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0572-2     Document Type: Article

References (39)

1. Statistics South Africa. Mid-year population estimates 2011. 2011. http://www.statssa.gov.za/publications/P0302/P03022011.pdf.
2. World Health Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3. 2010. http://whqlibdoc.who.int/publications/2010/ 9789241599191-eng.pdf.
3. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis - 2011 update. WHO/HTM/TB/2011.6. 2011. http://whqlibdoc.who.int/publications/2011/9789241501583-eng.pdf.
4. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283:2537-45.
5. Bonnet M, Pardini M, Meacci F, Orrù G, Yesilkaya H, Jarosz T, Andrew PW, Barer M, Checchi F, Rinder H, Orefici G, Rüsch-Gerdes S, Fattorini L, Oggioni MR, Melzer J, Niemann S, Varaine F. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS One. 2011;6:e23081.
6. Pooran A, Pieterson E, Davids M, Theron G, Dheda K. What is the cost of diagnosis and management of drug resistant tuberculosis in South Africa? PLoS One. 2013;8:e54587.
7. Bang D, Lillebaek T, Thomsen VØ, Andersen AB. Multidrug-resistant tuberculosis: treatment outcome in Denmark, 1992-2007. Scand J Infect Dis. 2010;42:288-93.
8. Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, Hoffmann H, Kirsten D, Schaberg T, Ruesch-Gerdes S, Lange C; German TBNET Group. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis. 2008;14:1700-6.
9. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, Gandhi NR, Galvani AP. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61.
10. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, Benedetti A, Burgos M, Centis R, Chan ED, Chiang CY, Cox H, D'Ambrosio L, DeRiemer K, Dung NH, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia ML, Gandhi N, Granich RM, Hollm-Delgado MG, Holtz TH, Iseman MD, Jarlsberg LG, Keshavjee S, Kim HR, Koh WJ, Lancaster J, Lange C, de Lange WC, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin SP, Mitnick CD, Narita M, O'Riordan P, Pai M, Palmero D, Park SK, Pasvol G, Peña J, Pérez- Guzmán C, Quelapio MI, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin SS, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand MJ, Tabarsi P, Tupasi TE, van Altena R, Van der Walt M, Van der Werf TS, Vargas MH, Viiklepp P, Westenhouse J, Yew WW, Yim JJ; Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med. 2012;9:e1001300.
11. Brust JC, Gandhi NR, Carrara H, Osburn G, Padayatchi N. High treatment failure and default rates for patients with multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa, 2000-2003. Int J Tuberc Lung Dis. 2010;14:413-9.
12. Farley JE, Ram M, Pan W, Waldman S, Cassell GH, Chaisson RE, Weyer K, Lancaster J, Van der Walt M. Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One. 2011;6:e20436.
13. Satti H, McLaughlin MM, Hedt-Gauthier B, Atwood SS, Omotayo DB, Ntlamelle L, Seung KJ. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS One. 2012;7:e46943.
14. Gandhi NR, Andrews JR, Brust JC, Montreuil R, Weissman D, Heo M, Moll AP, Friedland GH, Shah NS. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2012;16:90-7.
15. Shean KP, Willcox PA, Siwendu SN, Laserson KF, Gross L, Kammerer S, Wells CD, Holtz TH. Treatment outcome and follow-up of multidrug-resistant tuberculosis patients, West Coast/Winelands, South Africa, 1992-2002. Int J Tuberc Lung Dis. 2008;12:1182-9.
16. World Health Organization (WHO) Guidelines for the programmatic management of drug-resistant tuberculosis - emergency update 2008. WHO/HTM/TB/2008.402. 2008. http://whqlibdoc.who.int/publications/2008/ 9789241547581-eng.pdf.
17. Van Deun A, Salim MA, Das AP, Bastian I, Portaels F. Results of a standardised regimen for multidrug-resistant tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2004;8:560-7.
18. Shin SS, Furin JJ, Alcántara F, Bayona J, Sánchez E, Mitnick CD. Long-term follow-up for multidrug-resistant tuberculosis. Emerg Infect Dis. 2006;12:687-8.
19. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, Casali L, Fiorentini F, Codecasa LR, Migliori GB. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis. 2005;9:507-13.
20. Mitnick CD, Franke MF, Rich ML, Alcantara Viru FA, Appleton SC, Atwood SS, Bayona JN, Bonilla CA, Chalco K, Fraser HS, Furin JJ, Guerra D, Hurtado RM, Joseph K, Llaro K, Mestanza L, Mukherjee JS, Muñoz M, Palacios E, Sanchez E, Seung KJ, Shin SS, Sloutsky A, Tolman AW, Becerra MC. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLoS One. 2013;8:e58664.
21. Weyer K. DOTs-Plus for standardised management of multidrug-resistant tuberculosis in South Africa. Policy guidelines. Medical Research Council, Pretoria. 2004. http://www.sahealthinfo.org/tb/mdrtbguidelines.pdf.
22. Rodriguez M, Monedero I, Caminero JA, Encarnación M, Dominguez Y, Acosta I, Muñoz E, Camilo E, Martinez-Selmo S, de los Santos S, del Granado M, Casals M, Cayla J, Marcelino B. Successful management of multidrug-resistant tuberculosis under programme conditions in the Dominican Republic. Int J Tuberc Lung Dis. 2013;17:520-5.
23. Nkosi D, Janssen S, Padanilam X, Louw R, Menezes CN, Grobusch MP. Factors influencing specialist care referral of multidrug- and extensively drug-resistant tuberculosis patients in Gauteng/South Africa: a descriptive questionnaire-based study. BMC Health Serv Res. 2013;13:268.
24. Padayatchi N, Friedland G. Decentralised management of drug-resistant tuberculosis (MDR- and XDR-TB) in South Africa: an alternative model of care. Int J Tuberc Lung Dis. 2008;12:978-80.
25. Heller T, Lessells RJ, Wallrauch CG, Bärnighausen T, Cooke GS, Mhlongo L, Master I, Newell ML. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis. 2010;14:420-6.
26. Brust JC, Shah NS, Scott M, Chaiyachati K, Lygizos M, van der Merwe TL, Bamber S, Radebe Z, Loveday M, Moll AP, Margot B, Lalloo UG, Friedland GH, Gandhi NR. Integrated, home-based treatment for MDR-TB and HIV in rural South Africa: an alternate model of care. Int J Tuberc Lung Dis. 2012;16:998-1004.
27. Said HM, Kock MM, Ismail NA, Mphahlele M, Baba K, Omar SV, Osman AG, Hoosen AA, Ehlers MM. Molecular characterization and second-line antituberculosis drug resistance patterns of multidrug-resistant Mycobacterium tuberculosis isolates from the northern region of South Africa. J Clin Microbiol. 2012;50:2857-62.
28. Marais BJ, Mlambo CK, Rastogi N, Zozio T, Duse AG, Victor TC, Marais E, Warren RM. Epidemic spread of multidrug-resistant tuberculosis in Johannesburg, South Africa. J Clin Microbiol. 2013;51:1818-25.
29. Chihota VN, Müller B, Mlambo CK, Pillay M, Tait M, Streicher EM, Marais E, van der Spuy GD, Hanekom M, Coetzee G, Trollip A, Hayes C, Bosman ME, Gey van Pittius NC, Victor TC, van Helden PD, Warren RM. Population structure of multi- and extensively drug-resistant Mycobacterium tuberculosis strains in South Africa. J Clin Microbiol. 2012;50:995-1002.
30. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcón E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005;9:640-5.
31. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, Zalesky R. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J. 1998;12:505-10.
32. Kliiman K, Altraja A. Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB. Eur Respir J. 2009;33:1085-94.
33. Holtz TH, Lancaster J, Laserson KF, Wells CD, Thorpe L, Weyer K. Risk factors associated with default from multidrug-resistant tuberculosis treatment, South Africa, 1999-2001. Int J Tuberc Lung Dis. 2006;10:649-55.
34. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80.
35. Thiam S, LeFevre AM, Hane F, Ndiaye A, Ba F, Fielding KL, Ndir M, Lienhardt C. Effectiveness of a strategy to improve adherence to tuberculosis treatment in a resource-poor setting: a cluster randomized controlled trial. JAMA. 2007;297:380-6.
36. O'Donnell MR, Padayatchi N, Master I, Osburn G, Horsburgh CR. Improved early results for patients with extensively drug-resistant tuberculosis and HIV in South Africa. Int J Tuberc Lung Dis. 2009;13:855-61.
37. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis. 2004;190:1670-6.
38. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, Wong M, Padanilam X, Dziwiecki A, van Helden PD, Siwendu S, Jarand J, Menezes CN, Burns A, Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 2010;375:1798-807.
39. Ebonwu JI, Tint KS, Ihekweazu C. Low treatment initiation rates among multidrug-resistant tuberculosis patients in Gauteng, South Africa, 2011. Int J Tuberc Lung Dis. 2013;17:1043-8.